https://healthnewsofalabama.com/article/911074338-askbio-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meeting
AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual...
https://support.annualmeeting.asgct.org/asgct2025/public/Content.aspx?ID=502&sortMenu=101001
ASGCT 28th Annual Meeting
asgctannualmeeting
https://support.annualmeeting.asgct.org/asgct2025/Public/eBooth.aspx?IndexInList=249&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=103602&Nav=False
ASGCT 28th Annual Meeting
asgctannualmeeting
https://medically.roche.com/nz/en/neuroscience/congresses/asgct-2024.html
ASGCT 2024
asgct
https://support.annualmeeting.asgct.org/asgct2025/Public/Exhibitors.aspx?CatID=8
ASGCT 28th Annual Meeting: Exhibitors
annual meetingasgctexhibitors
https://thebiocalendar.com/event/asgct-annual-meeting/
ASGCT Annual Meeting - The BioCalendar
The ASGCT Annual Meeting is the leading global event for professionals in gene and cell therapy, hosted by the American Society of Gene + Cell Therapy (ASGCT)...
annual meetingasgct
https://www.asgardthx.com/asgard-therapeutics-announces-oral-presentation-at-asgct-2026-showcasing-advanced-preclinical-data-on-at-108-its-first-in-class-off-the-shelf-gene-based-cancer-immunotherapy/
Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data...
Apr 28, 2026 - Asgard Therapeutics today announces it will present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy,...
https://nanoporetech.com/es/about/events/conferences/asgct-2025
ASGCT 2025 | Oxford Nanopore Technologies
Oxford Nanopore Technologies are exhibiting at ASGCT 2025 in May 2025.
oxford nanoporeasgcttechnologies
https://support.annualmeeting.asgct.org/asgct2025/public/eBooth.aspx?IndexInList=179&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=102777&Nav=False
ASGCT 28th Annual Meeting
asgctannualmeeting
https://support.annualmeeting.asgct.org/asgct2025/Public/eBooth.aspx?IndexInList=184&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=102804&Nav=False
ASGCT 28th Annual Meeting
asgctannualmeeting
https://support.annualmeeting.asgct.org/asgct2025/public/Content.aspx?ID=478&sortMenu=102004
ASGCT 28th Annual Meeting
asgctannualmeeting
https://www.neushen.com/news/2024/neushen-therapeutics-announces-four-presentations-at-asgct-annual-meeting.html
NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting|NeuShen...
NeuShen Therapeutics We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting...
therapeuticsannouncesfourpresentations
https://hawaiihealthdigest.com/article/911074338-askbio-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meeting
AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual...
https://web.genewiz.com/tradeshow/asgct
ASGCT 2026 | GENEWIZ
Join GENEWIZ at the ASGCT Annual Meeting 2026 in Boston, MA to explore end-to-end multiomics and synthesis solutions.
asgct
https://support.annualmeeting.asgct.org/asgct2025/Public/Content.aspx?ID=502&sortMenu=101001
ASGCT 28th Annual Meeting
asgctannualmeeting
https://www.biospace.com/hc-bioscience-presents-preclinical-data-at-asgct-showing-strong-potential-in-hemophilia-a-using-trna-based-protein-editing-platform
hC Bioscience Presents Preclinical Data at ASGCT Showing Strong Potential in Hemophilia A Using...
May 9, 2024 - hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, presented...
https://healthcaretodaymontana.com/article/911074338-askbio-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meeting
AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual...
https://www.dyne-tx.com/news/dyne-therapeutics-presents-new-in-vivo-data-from-dyne-101-at-asgct-annual-meeting-demonstrating-low-monthly-dosing-leads-to-robust-dmpk-rna-knockdown/
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low...
Jan 20, 2026 - - Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - WALTHAM,...